单位:[1]Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China[2]Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[3]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Inst Hematol, State Key Lab Expt Hematol,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China[4]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Blood Dis Hosp, Tianjin, Peoples R China[5]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[6]Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China[7]Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC,Canc Hosp, Hangzhou, Peoples R China浙江省肿瘤医院[8]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China[9]Sichuan Univ, West China Hosp, Chengdu, Peoples R China四川大学华西医院[10]Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Nanjing, Peoples R China江苏省人民医院[11]Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China浙江大学医学院附属第一医院[12]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[13]Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China[14]Jilin Univ, Hosp 1, Changchun, Peoples R China[15]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China[16]Univ Melbourne, Peter MacCallum Canc Ctr, St Vincents Hosp, Melbourne, Vic, Australia[17]North Shore Hosp, Auckland, New Zealand[18]MD Anderson Canc Ctr, Houston, TX USA[19]Univ Michigan, Ann Arbor, MI 48109 USA[20]Monash Univ, Monash Hlth, Clayton, Vic, Australia[21]BeiGene Beijing Co Ltd, Beijing, Peoples R China
第一作者单位:[1]Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Song Yuqin,Zhou Keshu,Zou Dehui,et al.Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis[J].BLOOD.2022,140:6501-6503.doi:10.1182/blood-2022-162135.
APA:
Song, Yuqin,Zhou, Keshu,Zou, Dehui,Li, Dengju,Hu, Jianda...&Zhu, Jun.(2022).Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis.BLOOD,140,
MLA:
Song, Yuqin,et al."Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis".BLOOD 140.(2022):6501-6503